ADT SIDE EFFECTS
MANAGEMENT GUIDE
ADT produces a consistent and predictable set of side effects — the consequence of profound testosterone deprivation. Every side effect on this list is manageable. The key is anticipation: knowing what is coming, starting prevention early, and acting promptly when symptoms arise.
analyticsAt a Glance
- check_circleHot flushes affect 50–80% of ADT patients — pharmacological management is highly effective
- check_circleBone loss of 2–3% per year on ADT — DEXA monitoring, calcium/vitamin D, and bisphosphonates or denosumab are the standard prevention strategy
- check_circleCardiovascular risk rises with ADT duration — metabolic monitoring and exercise are evidence-based mitigation strategies
- check_circleSexual dysfunction (loss of libido, erectile dysfunction) affects nearly all patients — PDE5 inhibitors and vacuum devices remain useful
Why ADT Causes What It Causes: The Biology of Testosterone Deprivation
Testosterone has roles far beyond prostate cancer cell stimulation — it maintains bone density, supports muscle mass, regulates fat distribution, contributes to cardiovascular health, and drives libido. When ADT reduces testosterone to castrate levels, every tissue that testosterone normally supports is affected. Understanding the biology of each side effect makes the management rationale clear and motivates proactive intervention.
“Every ADT side effect is a consequence of removing something testosterone was doing — and each one has a specific pharmacological or lifestyle strategy that partially restores that function. ADT side effects are not inevitable suffering; they are a management challenge with available tools.”
Why Side Effects Are Predictable
Testosterone deprivation causes the same physiological changes regardless of how it is achieved — GnRH agonist, antagonist, or orchiectomy all produce the same side-effect profile at the same castrate testosterone level. What varies is the onset speed (antagonists are faster) and whether the effects are permanent (orchiectomy) or reversible (intermittent GnRH agonist therapy).
Why Early Intervention Matters
Bone loss begins within the first 3–6 months of ADT and accelerates in the first year — starting calcium, vitamin D, and DEXA monitoring at ADT initiation rather than waiting for a fracture prevents the most clinically significant long-term consequence. The same principle applies to cardiovascular risk monitoring and hot flush management — proactive prevention is more effective than reactive treatment.
ADT Side Effects: Comprehensive Management Reference
A structured guide to every major ADT side effect — with frequency, mechanism, and the most evidence-based management strategies.
| Side Effect | Frequency | Mechanism | Evidence-Based Management |
|---|---|---|---|
| Hot flushes and night sweats | 50–80% | Hypothalamic thermoregulatory dysfunction from oestrogen/androgen deprivation | Venlafaxine 75 mg/day (best evidence); medroxyprogesterone acetate 20 mg/day (highly effective, caution in metastatic disease); cyproterone acetate 50–100 mg/day; gabapentin 300 mg TDS; oxybutynin 5 mg at night |
| Bone mineral density loss | Universal — 2–3% per year | Testosterone supports osteoblast activity; castration accelerates bone resorption | DEXA at baseline and every 1–2 years; calcium 1,200 mg + vitamin D 1,000 IU daily from Day 1; zoledronic acid 4 mg IV 6-monthly or denosumab 60 mg SC 6-monthly if T-score <–2.0 or high fracture risk |
| Fatigue and reduced energy | 40–60% | Direct androgen-deprivation effect on muscle and CNS energy regulation; anaemia contribution | Supervised aerobic and resistance exercise (Level 1 evidence — significantly reduces ADT fatigue); screen and treat anaemia; optimise sleep; exclude depression |
| Muscle loss and fat gain | Universal over time | Testosterone maintains lean body mass; castration shifts body composition toward fat | Structured resistance exercise twice weekly; protein-adequate diet; refer to exercise physiologist specialising in oncology |
| Erectile dysfunction | ~85% at 3 months | Loss of androgen-driven erections; endothelial changes in penile vasculature | PDE5 inhibitors (sildenafil, tadalafil) — most effective if started early; vacuum erection devices; intracavernosal alprostadil; psychological support / couples therapy |
| Loss of libido (reduced desire) | ~95% | Testosterone is the primary driver of sexual desire — castrate levels eliminate it | Psychological support; education that desire will return if ADT is discontinued; PDE5 inhibitors address erectile function but not libido directly |
| Gynaecomastia (breast tenderness/growth) | 20–40% | Peripheral oestrogen unopposed by testosterone — oestrogen stimulates breast tissue | Prophylactic radiotherapy to breast buds before ADT initiation (most effective, especially with anti-androgens); tamoxifen 20 mg/day reduces gynaecomastia significantly; surgical treatment (liposuction/mastectomy) if severe |
| Cognitive effects | 20–30% | Testosterone supports verbal memory and executive function; some evidence for ADT-related cognitive change | Exercise (protective); cognitive stimulation; screen for depression; avoid unnecessary sedating medications; reassess if severe |
| Depression and mood changes | 15–20% | Testosterone has antidepressant-like CNS effects; social/identity impact of androgen deprivation | Exercise; psychological support; antidepressants (SSRIs — venlafaxine dual benefit for hot flushes); psychiatry referral if severe |
| Cardiovascular risk increase | Cumulative with duration | Insulin resistance, dyslipidaemia, increased fat mass, possible direct cardiac effects | Blood pressure q3 months; fasting glucose and lipids annually; aerobic exercise 150 min/week; statins if dyslipidaemia; relugolix if pre-existing CV disease; smoking cessation; weight management |
| Anaemia | ~40% (mild) | Testosterone stimulates erythropoietin — castration reduces red cell production | Usually mild and clinically insignificant; check FBC annually; iron replacement if iron-deficient; EPO rarely needed |
Bone Health During ADT: A Structured Prevention Programme
ADT-associated bone loss is the most clinically significant long-term adverse effect — fractures in older men with prostate cancer carry high morbidity and mortality. The following programme should start at the same time as ADT.
- 1
DEXA Scan at ADT Initiation
Dual-energy X-ray absorptiometry at the lumbar spine and hip establishes baseline bone density and provides a T-score for fracture risk assessment. Men with T-score below –1.0 at ADT initiation are already at elevated fracture risk and require more aggressive prevention.
- 2
Calcium and Vitamin D from Day 1
Calcium 1,000–1,200 mg daily (combined dietary + supplemental) and vitamin D 800–1,000 IU daily should start with the first ADT dose — not when bone loss is detected. Check 25-OH vitamin D at baseline and repletion to >75 nmol/L reduces fall risk as well as protecting bone.
- 3
FRAX Score Assessment
The FRAX tool (www.shef.ac.uk/FRAX) incorporates T-score, age, weight, and other risk factors to calculate 10-year fracture probability. A 10-year major osteoporotic fracture risk >20% or hip fracture risk >3% triggers pharmacological bone protection.
- 4
Pharmacological Bone Protection When Indicated
Zoledronic acid 4 mg IV 6-monthly or denosumab 60 mg SC 6-monthly are the two approved agents for ADT-related bone loss. Denosumab is marginally more effective but requires careful scheduling to prevent rebound hypercalcaemia if discontinued. Prescribe alongside dental review (bisphosphonate/denosumab risk of osteonecrosis of the jaw — rare but requires pre-dental clearance).
- 5
Repeat DEXA at 12–24 Months
Annual or biennial DEXA monitors bone density trajectory — confirming whether calcium/vitamin D are sufficient, whether pharmacological treatment is working, and whether fracture risk is increasing. Adjust treatment based on DEXA trend, not a single measurement.
ADT Side Effects: Key Numbers
Frequency and impact figures from clinical trials and population-based studies.
- 8–10%Annual bone mineral density loss on continuous ADT (without prevention)Among the highest rates of bone loss of any medical treatment — requiring mandatory prevention from Day 1 of ADT.
- 40%Reduction in ADT-related fatigue with supervised exercise (RCT evidence)Exercise is the only intervention with Level 1 evidence for fatigue improvement during ADT — more effective than pharmacological interventions.
- ~95%Of men experience significant reduction in sexual desire within 3 monthsNear-universal libido reduction under ADT — setting realistic expectations before starting treatment significantly improves adjustment and relationship adaptation.
- 90%Reduction in gynaecomastia risk with prophylactic breast radiotherapyBilateral breast bud irradiation (8–12 Gy in 1–2 fractions) before anti-androgen initiation is highly effective — far more so than treatment after gynaecomastia has established.
More from the Hormone Therapy Resource Library
Continue exploring ADT management and prostate cancer treatment options.
- Androgen Deprivation Therapy (ADT): A Complete Patient Guide
- Enzalutamide vs Abiraterone vs Darolutamide: Next-Generation Hormonal Therapies
- How Long Should I Take Hormone Therapy? Duration Decisions
- What Is Hormone Therapy for Cancer and How Does It Work?
- Hormone Therapy for Prostate Cancer — Complete Guide
- PSMA-Targeted Therapy for Prostate Cancer
Frequently Asked Questions
Common questions from patients and partners about managing ADT side effects.
Managing ADT Side Effects
Can I do strength training while on ADT? Is it safe?
Not only is strength training safe during ADT — it is strongly recommended. Resistance exercise is the most effective intervention for the muscle loss, fat gain, and fatigue that ADT causes. Randomised controlled trials (including the ENGAGE trial) show that supervised resistance exercise twice weekly significantly preserves lean body mass, reduces fatigue, and improves quality of life and physical function compared to usual care. Aerobic exercise adds cardiovascular protection and further fatigue benefit. Ideally, refer to an oncology exercise physiologist who can design a programme safe around any bone metastases or other physical limitations — but even self-directed walking and bodyweight exercise are beneficial. The goal is 150 minutes of moderate aerobic activity plus 2 sessions of resistance exercise per week.
Will my erections return if ADT is stopped?
Erectile function and libido both decline profoundly on ADT and typically begin recovering when ADT is stopped — but full recovery depends on several factors: how long ADT was given, age at ADT initiation, pre-ADT erectile function baseline, and whether testosterone returns to normal levels after stopping. In men on shorter ADT courses (6–18 months for local treatment), testosterone typically recovers to normal levels within 3–12 months of stopping, and sexual function often returns — though not always to pre-ADT levels, particularly in older men. In men who have been on continuous long-term ADT, testosterone recovery may be slower or incomplete. PDE5 inhibitors (sildenafil, tadalafil) can be started during ADT to maintain penile vascular health and should be continued after ADT stops to support recovery.
My partner is struggling with the changes ADT has caused — what support is available?
The impact of ADT on sexual function, emotional regulation, and body image affects both the patient and their partner — and this is recognised in international guidelines. Specific resources include: couples counselling or psychosexual therapy with a therapist experienced in cancer-related sexual dysfunction; support groups for partners of men with prostate cancer (Prostate Cancer UK, PCF in the US); oncology nurse specialist or clinical nurse practitioner consultations focused on sexual health; and for patients and partners who want to remain sexually active, specialist sex therapy can navigate changes in sexual function caused by ADT with practical, evidence-based strategies.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Need Help Managing ADT Side Effects?
CancerFax connects patients with specialist oncologists and supportive care teams who can review your ADT side-effect burden and implement evidence-based management strategies — including bone health programmes, cardiovascular monitoring, and sexual health support.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.